CHAMPIONS ONCOLOGY, INC. (CSBR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
50/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCSBR / S&P 7.13% / 15.20% |
LoseCSBR / S&P 4.36% / 15.00% |
LoseCSBR / S&P -121.88% / 50.40% |
| 2026-Q10/3 |
LoseCSBR / S&P -16.79% / -4.33% |
LoseCSBR / S&P -1.10% / 11.30% |
LoseCSBR / S&P -136.36% / 27.70% |
| 2025-Q42/3 |
WinCSBR / S&P 6.64% / 2.65% |
WinCSBR / S&P 9.06% / 9.00% |
LoseCSBR / S&P -383.33% / 13.40% |
| 2025-Q31/3 |
LoseCSBR / S&P -12.08% / 8.12% |
WinCSBR / S&P 10.11% / 4.61% |
LoseCSBR / S&P -176.92% / 13.45% |
| 2025-Q21/3 |
LoseCSBR / S&P -15.09% / 10.94% |
WinCSBR / S&P 13.54% / 4.83% |
LoseCSBR / S&P -159.26% / 10.63% |
| 2025-Q12/3 |
WinCSBR / S&P 1.28% / -4.27% |
WinCSBR / S&P 19.03% / 4.98% |
LoseCSBR / S&P -161.11% / 10.57% |
| 2024-Q42/3 |
WinCSBR / S&P 75.98% / 2.41% |
WinCSBR / S&P 7.19% / 5.25% |
LoseCSBR / S&P -91.55% / 6.15% |
| 2024-Q30/3 |
LoseCSBR / S&P -5.80% / 5.89% |
LoseCSBR / S&P -1.96% / 5.89% |
LoseCSBR / S&P -53.57% / 6.11% |
| 2024-Q22/3 |
WinCSBR / S&P 5.51% / 4.28% |
LoseCSBR / S&P -6.90% / 5.38% |
WinCSBR / S&P 38.46% / 5.12% |
| 2024-Q11/3 |
LoseCSBR / S&P -12.81% / 10.56% |
LoseCSBR / S&P -8.29% / 5.71% |
WinCSBR / S&P 227.27% / 5.59% |
| 2023-Q40/3 |
LoseCSBR / S&P -9.50% / 11.69% |
LoseCSBR / S&P -7.61% / 6.81% |
LoseCSBR / S&P -7200.00% / 7.78% |
| 2023-Q31/3 |
WinCSBR / S&P -2.66% / -3.27% |
LoseCSBR / S&P 2.10% / 7.52% |
LoseCSBR / S&P -1966.67% / -5.03% |
| 2023-Q22/3 |
WinCSBR / S&P 58.71% / 8.74% |
WinCSBR / S&P 9.69% / 9.50% |
LoseCSBR / S&P -1075.00% / -8.57% |
| 2023-Q11/3 |
LoseCSBR / S&P -10.86% / 7.50% |
WinCSBR / S&P 14.70% / 10.77% |
LoseCSBR / S&P -2300.00% / -15.69% |
| 2022-Q41/3 |
LoseCSBR / S&P -39.87% / 7.56% |
WinCSBR / S&P 21.80% / 11.88% |
LoseCSBR / S&P -66.67% / -17.99% |
| 2022-Q32/3 |
LoseCSBR / S&P -6.25% / -4.88% |
WinCSBR / S&P 20.72% / 13.47% |
WinCSBR / S&P 200.00% / -1.41% |
| 2022-Q23/3 |
WinCSBR / S&P -1.60% / -16.10% |
WinCSBR / S&P 19.66% / 13.71% |
WinCSBR / S&P 33.33% / 11.04% |
| 2022-Q12/3 |
WinCSBR / S&P -2.75% / -4.60% |
WinCSBR / S&P 19.30% / 15.97% |
LoseCSBR / S&P -109.09% / 42.23% |
| 2021-Q41/3 |
LoseCSBR / S&P -18.12% / 11.03% |
WinCSBR / S&P 18.68% / 15.00% |
LoseCSBR / S&P -120.00% / 96.40% |
| 2021-Q31/3 |
LoseCSBR / S&P -0.68% / 0.58% |
WinCSBR / S&P 22.37% / 10.77% |
LoseCSBR / S&P -107.69% / 69.42% |
| 2021-Q21/3 |
LoseCSBR / S&P -9.03% / 8.55% |
WinCSBR / S&P 27.76% / 6.58% |
LoseCSBR / S&P -115.00% / 51.81% |
| 2021-Q12/3 |
LoseCSBR / S&P 4.73% / 6.17% |
WinCSBR / S&P 26.15% / -1.06% |
WinCSBR / S&P 266.67% / 7.39% |
| 2020-Q43/3 |
WinCSBR / S&P 16.65% / 12.15% |
WinCSBR / S&P 31.26% / -3.72% |
WinCSBR / S&P 66.67% / -33.42% |
| 2020-Q32/3 |
LoseCSBR / S&P -3.24% / 8.93% |
WinCSBR / S&P 26.66% / -2.04% |
WinCSBR / S&P 44.44% / -27.10% |
| 2020-Q22/3 |
WinCSBR / S&P 29.19% / 20.54% |
WinCSBR / S&P 18.68% / -0.46% |
LoseCSBR / S&P -2100.00% / -27.11% |
| 2020-Q13/3 |
WinCSBR / S&P -11.16% / -19.60% |
WinCSBR / S&P 28.11% / 3.47% |
WinCSBR / S&P 50.00% / -14.75% |
| 2019-Q43/3 |
WinCSBR / S&P 47.43% / 9.07% |
WinCSBR / S&P 24.38% / 5.36% |
WinCSBR / S&P 2594073385365405184.00% / 2.99% |
| 2019-Q32/3 |
LoseCSBR / S&P -27.84% / 1.70% |
WinCSBR / S&P 28.68% / 5.02% |
WinCSBR / S&P 200.00% / 0.21% |
| 2019-Q21/3 |
LoseCSBR / S&P -20.02% / 4.30% |
WinCSBR / S&P 33.73% / 6.64% |
LoseCSBR / S&P -107.69% / 8.65% |
| 2019-Q11/3 |
WinCSBR / S&P 25.35% / 13.65% |
LoseCSBR / S&P CSBR unavailable / 8.12% |
LoseCSBR / S&P CSBR unavailable / 14.29% |
| 2018-Q40/3 |
LoseCSBR / S&P -55.29% / -13.52% |
LoseCSBR / S&P CSBR unavailable / 9.05% |
LoseCSBR / S&P CSBR unavailable / 18.23% |
| 2018-Q31/3 |
WinCSBR / S&P 175.55% / 7.71% |
LoseCSBR / S&P CSBR unavailable / 10.21% |
LoseCSBR / S&P CSBR unavailable / 19.06% |
| 2018-Q21/3 |
WinCSBR / S&P 74.18% / 3.43% |
LoseCSBR / S&P CSBR unavailable / 9.03% |
LoseCSBR / S&P CSBR unavailable / 14.46% |
| 2018-Q10/3 |
LoseCSBR / S&P -6.19% / -0.76% |
LoseCSBR / S&P CSBR unavailable / 7.68% |
LoseCSBR / S&P CSBR unavailable / 12.46% |
| 2017-Q40/3 |
LoseCSBR / S&P 5.72% / 6.64% |
LoseCSBR / S&P CSBR unavailable / 7.03% |
LoseCSBR / S&P CSBR unavailable / 13.82% |
| 2017-Q31/3 |
WinCSBR / S&P 42.80% / 4.48% |
LoseCSBR / S&P CSBR unavailable / 5.68% |
LoseCSBR / S&P CSBR unavailable / 17.57% |
| 2017-Q20/3 |
LoseCSBR / S&P -18.93% / 3.09% |
LoseCSBR / S&P CSBR unavailable / 4.83% |
LoseCSBR / S&P CSBR unavailable / 17.74% |
| 2017-Q11/3 |
WinCSBR / S&P 25.30% / 6.07% |
LoseCSBR / S&P CSBR unavailable / 3.67% |
LoseCSBR / S&P CSBR unavailable / 13.32% |
| 2016-Q41/3 |
WinCSBR / S&P 50.60% / 3.82% |
LoseCSBR / S&P CSBR unavailable / 2.09% |
LoseCSBR / S&P CSBR unavailable / 7.05% |
| 2016-Q30/3 |
LoseCSBR / S&P -21.86% / 3.85% |
LoseCSBR / S&P CSBR unavailable / 0.20% |
LoseCSBR / S&P CSBR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CSBR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -26.18% | 20.78% |
| Annualized return | -26.18% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CSBR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -51.73% | 83.14% |
| Annualized return | -13.56% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CSBR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 223.87% | 319.30% |
| Annualized return | 12.47% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |